ClinConnect ClinConnect Logo
Search / Trial NCT06438068

Influence of Modern Colon Hydrotherapy on Intestinal Transit

Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · May 26, 2024

Trial Information

Current as of July 25, 2025

Not yet recruiting

Keywords

Constipation Internal Hydrotherapy Radiopaque Media Functional Colonic Diseases

ClinConnect Summary

This clinical trial is looking at the effects of a treatment called Modern Colon Hydrotherapy on people who suffer from functional constipation, which is a long-term issue with bowel movements. The goal is to see if this therapy can help improve how quickly food and waste move through the digestive system. The trial is not yet recruiting participants, but it will involve adults aged 20 to 60 who have experienced functional constipation for more than five years.

To be eligible for this trial, participants should not have taken antibiotics, prebiotics, probiotics, or laxatives in the past month, and they should not be pregnant or have certain serious medical conditions like severe gastrointestinal issues or heart problems. If you join the trial, you can expect to receive treatment and contribute to important research that may help others with similar digestive issues in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients between 20 and 60 years of age with functional constipation of more than 5 years of evolution.
  • Exclusion Criteria:
  • Taking any type of antibiotic in the last month
  • Taking prebiotics or probiotics products in the last month.
  • Taking laxatives in the last month.
  • Undergoing any medicinal treatment
  • Pregnancy
  • Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.

About Universidad Complutense De Madrid

The Universidad Complutense de Madrid (UCM) is a prestigious academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a prominent sponsor of clinical trials, UCM leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring the highest standards of ethics and scientific rigor in its clinical research initiatives. UCM's dedication to education and research excellence positions it as a leader in the development of new therapeutic interventions and health solutions.

Locations

Madrid, , Spain

Patients applied

0 patients applied

Trial Officials

Isidro Fernández-López, PhD.

Principal Investigator

Universidad Complutense de Madrid

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported